IntroductionThe benefits of specialist assessment and management have yet to be evaluated within the biologic era of UK severe asthma treatment, and potential disparities have not been considered.MethodsIn an uncontrolled before-and-after study, we compared asthma symptoms (asthma control questionnaire [ACQ6]), exacerbations, unscheduled secondary care use, lung function (FEV1) and oral corticosteroid (OCS) dose after one year. We compared outcomes by sex, age (18–34, 35–49, 50–64, 65+ years), ethnicity (Caucasian versus Non- Caucasian) and hospital site after adjusting for demographics and variation in biologic therapy use.Results1,140 patients were followed-up for 1,370 person-years from twelve specialist centres. At annual review, ACQ6 score was reduced by a median of 0.7 (IQR:0.0, 1.5), exacerbations by 75% (IQR: 33%, 100%) and unscheduled secondary care by 100% (IQR:67%, 100%). FEV1 increased by a median of 20 mL (IQR:-200, 340) while OCS dose decreased for 67% of patients. Clinically meaningful improvements occurred across almost all patients, including those not receiving biologic therapy. There was little evidence of differences across demographic groups, although those aged over 65 demonstrated larger reductions in exacerbations (69% versus 52%; p<0.001) and unscheduled care use (77% versus 50%; p<0.001) compared to patients aged under 34 years. There were more than 2-fold differences between the best and worst performing centres across all study outcomes.ConclusionsSpecialist assessment and management is associated with substantially improved patient outcomes which are broadly consistent across demographic groups, and are not restricted to those receiving biologic therapy. Significant variation exists between hospitals which requires further investigation.